Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -3.93
- Piotroski Score 4.00
- Grade Buy
- Symbol (GOSS)
- Company Gossamer Bio, Inc.
- Price $0.67
- Changes Percentage (-3.56%)
- Change -$0.02
- Day Low $0.66
- Day High $0.72
- Year High $1.60
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/04/2025
- Fiscal Year End N/A
- Average Stock Price Target $4.00
- High Stock Price Target $5.00
- Low Stock Price Target $2.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.85
- Trailing P/E Ratio -0.65
- Forward P/E Ratio -0.65
- P/E Growth -0.65
- Net Income $-179,817,000
Income Statement
Quarterly
Annual
Latest News of GOSS
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Wedding guests gasp as woman calls out family gossip about her in speech
Tamanna, a 32-year-old from Sydney, Australia, gained viral attention for her wedding speech criticizing her community's gossiping habits....
By Newsweek | 4 days ago -
Search for 'Gossip Girl' actor Chanel Maya Banks who was reported missing is over, police say
Chanel Maya Banks, known for roles in TV shows like "Gossip Girl" and "Blue Bloods," was reported missing but later found in Texas. Banks claimed she left to escape family abuse, despite family's sear...
By USA Today | 1 week ago -
Mark-Paul Gosselaar Evades Justice as He Pretends He's Not the Kidnapper in Chilling 'Found' Teaser (Exclusive)
In an exclusive teaser for the next episode of Found, Mark-Paul Gosselaar's character, Sir Evans, discusses his captivity by Gabi Mosely and his involvement with her firm M&A. Despite his actions, Sir...
By PEOPLE.com | 1 week ago
